TABLE 3.
Antibiotic resistance profiles of S. aureus isolates
| Antibiotic family(-ies)a | No. of isolates |
Clonal complex(es)b | Origin | No. of patients with both wound and nasal USA300 isolates | |
|---|---|---|---|---|---|
| MRSA | MSSA | ||||
| BLAs + CLI + ERY + LEV + TET | 0 | 1 | CC15 | Nasal | |
| BLAs + CLI + ERY + LEV | 4 | 2 | CC5, CC8, CC15 | Wound, nasal | 1 patient with USA300 |
| BLAs + ERY + TET | 1 | 2 | CC8, CC88 | Wound, nasal | 1 patient with USA300 |
| BLAs + ERY + LEV | 21 | 0 | CC5, CC8 | Wound, nasal | 2 patients with USA300, 1 patient with USA300-like |
| BLAs + CLI + ERY | 1 | 7 | CC5, CC8, CC15, CC30 | Wound, nasal | 1 patient with USA300 |
| BLAs + LEV + TMP-SMX | 1 | 0 | CC8 | Nasal | |
| BLAs + ERY | 7 | 5 | CC8, CC30, CC121 | Wound, nasal | 1 patient with USA300 |
| BLAs + TET | 3 | 1 | CC5, CC8 | Wound, nasal | 1 patient with USA300 |
| BLAs + TMP-SMX | 0 | 1 | CC8 | Nasal | |
a
BLAs, β-lactam antibiotics; penicillin, amoxicillin-clavulanic acid, cefazolin, and oxacillin in the case of MRSA isolates and penicillin alone for MSSA isolates. CLI, clindamycin; ERY, erythromycin; LEV, levofloxacin; TET, tetracycline; TMP-SMX, trimethoprim-sulfamethoxazole.
b
Clonal complex as defined by MLST. CC5, clonal complex of the HA-MRSA strain USA100 (“New York/Japan” clone); CC8, clonal complex of the CA-MRSA strain USA300 clone.